PF-Atlas › Clinical Trials › NCT00578565

Rituximab in Rheumatoid Arthritis Lung Disease

Rituximab · Phase 3

Registry ID
NCT00578565
Phase
Phase 3
Status
Completed
Drug / intervention
Rituximab
Sponsor
Eric Matteson
Start
2007-05
Enrollment
10
Locations
2

About this trial

This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physical exams and laboratory parameters. * Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological subtype) will be enrolled * The study involves 12 visits over 48 weeks * Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at six months.

View NCT00578565 on ClinicalTrials.gov →

Explore related

All Rituximab trialsAll IPF trials

Related trials

Rituximab — NCT01086540Rituximab — NCT01862926Rituximab — NCT02990286Rituximab — NCT05596786Rituximab — NCT03069248Rituximab — NCT01969409
Medical disclaimer. This page summarizes public trial data for NCT00578565 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.